MEDTRONIC ACTIVA IMPLANTABLE TREMOR CONTROL SYSTEM UNANIMOUSLY CLEARED BY FDA PANEL FOR UNILATERAL USE; PANEL WANTS MORE DATA ON BILATERAL INDICATION
This article was originally published in The Gray Sheet
Executive Summary
Medtronic plans to continue to pursue approval of a bilateral indication for its Activa implantable deep brain stimulator despite a rejection of that indication by an FDA advisory panel on March 14.
You may also be interested in...
External Science Review Prepares To Evaluate Stimulating Case Studies
An external review committee, charged with assessing CDRH's use of science in regulatory decisions, expects to review deep brain stimulation devices as part of an upcoming closed-door meeting slated for July 24-26.
External Science Review Prepares To Evaluate Stimulating Case Studies
An external review committee, charged with assessing CDRH's use of science in regulatory decisions, expects to review deep brain stimulation devices as part of an upcoming closed-door meeting slated for July 24-26.
Medtronic Activa Approvable With Conditions; Data Show Dyskinesia Drop Off
Medtronic's Activa Parkinson's control therapy system should be indicated for treatment only of "advanced levadopa (L-dopa) responsive" Parkinson's patients, FDA's Neurological Devices Panel recommended at a March 31 meeting in Rockville, Maryland.